TKThomas Koudstaal

Thomas Koudstaal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Thomas Koudstaal has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sotatercept in TBX4 Associated Heritable Pulmonary Arterial Hypertension: A Case Report of a Super Responder

    by Jop W. Schneijdenberg, Annemien E. van Den Bosch, Miriam E. Kap, Robert M. Kauling, Prewesh P. Chandoesing, Leon M. van Den Toorn, Bas J. Mathot, Thomas Koudstaal, Karin A. Boomars

    Pulmonary arterial hypertension (PAH) is a life‐threatening disease of the pulmonary arteries. Progressively increasing pulmonary artery pressure may lead to fatal failure of the right ventricle, necessitating aggressive drug treatment. Sotatercept, a novel drug for PAH‐targeted therapy, shows promising results in clinical trials. Nevertheless, efficacy in the heterogeneous PAH population and long‐term outcomes have yet to be investigated. This case report illustrates the life‐changing effects of sotatercept in a patient with heritable PAH associated with a TBX4 mutation. Our patient faced near immobility, oxygen dependency, and was listed for lung transplantation in November 2023. Following sotatercept administration from July 2024 onward, she started sporting activities and has been removed from the transplantation waiting list. Thereby, this case illustrates an exceptional response to sotatercept in a patient with TBX4‐associated heritable PAH. Positive effects persist 1 year after initiation without significant side effects.


  • Open Access

    Prognostic Value of Tricuspid Valve Regurgitation in Patients With Pulmonary Arterial Hypertension and CTEPH: A Longitudinal Study

    by Kevin M. Veen, Thomas Koudstaal, Paul M. Hendriks, Johanna Jm Takkenberg, Karin A. Boomars, Annemien E. van Den Bosch

    Aims: The prognostic value of functional tricuspid valve regurgitation (TR) in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (CTEPH) remains undetermined. This study aims to quantify the prognostic role of TR during follow-up in relation to right ventricle (RV) dysfunction on clinical outcomes. Methods and Results: Patients from our prospective cohort study with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension were included. The primary endpoint was a composite of death or lung transplantation. The longitudinal evolution of TR and RV dysfunction were modelled with generalized mixed-effect models, which were inserted in a cox model under the joint-modelling framework in order to investigate the association of TR and RV dysfunction with the endpoint. In total, 120 patients were included (median age:59, females:62%), with a mean follow-up of 3.2±2.1 years. 31 patients reached the endpoint (2 transplant, 29 mortality). On average the probability of moderate-to-severe TR decreased during follow-up, whereas the probability of moderate-to-severe RV dysfunction remained stable over time. The cumulative effect of moderate-to-severe TR (hazard ratio: 1.01 95%CI[1.00-1.01],P<0.001) and moderate-to-severe RV dysfunction (hazard ratio: 1.01 95%CI[1.00-1.01],P<0.001) was associated with the composite endpoint in univariable joint-models. In a multivariable joint-model with both the evolutions of TR and RV dysfunction only TR remained a significant predictor (hazard ratio: 1.01 95%CI[1.00-1.01],P<0.001). Conclusion: Persistent moderate-to-severe tricuspid valve regurgitation during follow-up predicts adverse outcomes and might be a better predictor of lung transplantation and mortality compared to right ventricle dysfunction.

  • DNGR1-Cre–mediated Deletion of Tnfaip3 /A20 in Conventional Dendritic Cells Induces Pulmonary Hypertension in Mice

    by Thomas Koudstaal, Jennifer A. C. van Hulst, Tridib Das, Stefan F. H. Neys, Daphne Merkus, Ingrid M. Bergen, Michiel A. de Raaf, Harm Jan Bogaard, Louis Boon, Geert van Loo, et al.

    Chronic perivascular inflammation is a prominent feature in the lungs of idiopathic pulmonary arterial hypertension. Although the proportions of conventional dendritic cells (cDCs) and plasmacytoid DCs are increased in idiopathic pulmonary arterial hypertension lungs, it remains unknown whether activated cDCs play a pathogenic role. The Tnfaip3 gene encodes the ubiquitin-binding protein A20, which is a negative regulator of NF-κB, critically involved in DC activation. Targeting of Tnfaip3/A20 in cDCs was achieved by Clec9a (DNGR1)-Cre–mediated excision of the Tnfaip3 gene in Tnfaip3DNGR1-KO mice. Mice were evaluated for signs of pulmonary hypertension (PH) using right heart catheterization, echocardiography, and measurement of the Fulton index. Inflammation was assessed by immunohistochemistry and flow cytometry. Pulmonary cDCs and monocyte-derived DCs from 31-week-old Tnfaip3DNGR1-KO mice showed modulated expression of cell surface activation markers compared with Tnfaip3DNGR1-WT mice. Tnfaip3DNGR1-KO mice developed elevated right ventricular systolic pressure and right ventricular hypertrophy. The lungs of these mice displayed increased vascular remodeling and perivascular and peribronchial immune cell infiltration resembling tertiary lymphoid organs. Proportions of activated T cells and expression of IL-1β, IL-6, and IL-10 were enhanced in the lungs of Tnfaip3DNGR1-KO mice. Autoreactive IgA and IgG1 was detected in BAL and autoreactive IgA recognizing pulmonary endothelial antigens was present in the serum of Tnfaip3DNGR1-KO mice. All signs of PH were ameliorated in Tnfaip3DNGR1-KO mice by anti–IL-6 antibody treatment. These results indicate that activation of the NF-κB pathway in DCs, through deletion of A20/Tnfaip3, leads to experimental PH with accompanied pulmonary inflammation in an IL-6–dependent fashion.


  • DNGR1-mediated deletion of A20/Tnfaip3 in dendritic cells alters T and B-cell homeostasis and promotes autoimmune liver pathology

    by Tridib Das, Ingrid M. Bergen, Thomas Koudstaal, Jennifer A.C. van Hulst, Geert van Loo, André Boonstra, Thomas Vanwolleghem, Patrick S.C. Leung, M. Eric Gershwin, Rudi W. Hendriks, et al.